statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Glenmark Pharmaceuticals Share Price | The share touched a 52-week high of Rs 1,095.95 and a 52-week low of Rs 516.65 on 25 April, 2024 and 26 April, 2023, respectively.

Glenmark Pharma shares gain on US FDA nod for acetaminophen, ibuprofen tablets

As per the latest Enforcement Report by the US Food and Drug Administration (USFDA), Lupin is recalling 26,352 bottles of Rifampin Capsules (300 mg), an antibiotic medication in the US market.

Lupin, Glenmark recall drugs in US market: USFDA

Lupin recalled 26,352 bottles of Rifampin capsules, used in the treatment of tuberculosis

Lupin, Glenmark, Natco recall products from US markets

KR Choksey is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 1266 in its research report dated April 05, 2024.

Buy Glenmark Pharmaceuticals; target of Rs 1266: KR Choksey

Being passionate about derivative after a decade of struggle, Shilpa Rout, Derivative Lead Analyst and AVP – Research at Prabhudas Lilladher, suggests taking Bull Call spread on Nifty monthly expiry with buying 22,500 CE buy and selling 23,100 CE.

Mantra by derivative lead analyst: Work religiously irrespective of temporary failures, have risk management systems in place

KR Choksey recommended Accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 984 in its research report dated February 22, 2024.

Accumulate Glenmark Pharmaceuticals; target of Rs 984: KR Choksey

Glenmark Pharma formed bullish candlestick pattern on the daily scale with above average volumes. The stock showed nice recovery in last four days after falling closer to 200-day EMA, and now traded above all key moving averages.

Trade Spotlight | How you should deal in Gujarat Ambuja Exports, Craftsman Automation, Glenmark Pharma today

The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement.

Glenmark launches antidiabetic drug in India

Priced at around Rs 100 for a standard dose of 1.2 mg (per day), this will lower the cost of therapy by approximately 70 percent

Glenmark launches biosimilar of anti-diabetic drug, vows to cut down therapy cost by 70%

Glenmark Pharma hit the highest level since 2017. The stock has formed long bullish candlestick pattern on the daily timeframe with strong volumes, and traded above all key moving averages.

Trade Spotlight | Strategy to trade in Lupin, Glenmark Pharma, Lemon Tree Hotels today

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. It operates through the India, North America, Latin America, Europe, and Rest of the World geographical segments. The company was founded by Gracias Saldanha on November 18, 1977 and is headquartered in Mumbai, India.

Watchers	206
52-Wk Low	581.00
52-Wk High	1,098.00

Volume	421,300.00
52-Wk High	1,098.00
52-Wk Low	581.00

Current Price	1,027.25
Prev Close	1,001.15
Open	1,002.85
Dividend Yield	0.54%
50-Day Moving Average	989.66
Beta	0.04
Avg. Volume	774,179.00
PE Ratio	-39.63

52-Week High	1,098.00
52-Week Low	581.00
Market Capitalization	282.09B
EPS	-25.22
Price to Book	3.02
Revenue Per Employee	8.35M
Enterprise Value/EBITDA	19.19

GLENMARK.NSE Glenmark Pharmaceuticals Ltd.

About

Feed

News

Sentiment

Fundamentals